GRAIL, Inc. (GRAL) Covered Calls

GRAIL, Inc. is a pioneering healthcare company focused on early cancer detection. The company’s flagship Galleri test uses high-intensity sequencing and data science to detect a shared cancer signal across more than 50 types of cancer from a single blood draw. As an independent entity following its spinoff from Illumina, GRAIL is dedicated to establishing multi-cancer early detection (MCED) as a new standard of care to improve global survival rates.

You can sell covered calls on GRAIL, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GRAL (prices last updated Mon 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

GRAIL, Inc. (GRAL) leads the multi-cancer early detection (MCED) market with its Galleri test. This liquid biopsy utilizes next-generation sequencing (NGS) and machine learning to identify DNA methylation patterns—a "biological signal" associated with cancer. Galleri can detect over 50 types of cancer, many of which lack routine screening, and accurately identifies the "cancer signal origin" to guide clinical follow-up.

In 2026, GRAIL is expanding its commercial reach through partnerships with major health systems, employers, and insurers. The company is advancing significant clinical evidence through large-scale trials like the NHS-Galleri study in the UK. These efforts are designed to validate the clinical utility of MCED for broad populations, a critical step for securing full FDA approval and widespread insurance coverage.

Competitive Landscape

The oncology market is shifting toward multi-cancer liquid biopsies. GRAIL benefits from an early-mover advantage and an extensive methylation dataset, creating a significant moat in a capital-intensive sector. Unlike many emerging peers, GRAL is highly liquid with an active options market, making it the primary vehicle for investors tracking the MCED sub-sector.

Key competitors and peers in the early detection and genomics space include:

1. Abbott Laboratories (ABT): A global diagnostics leader that bolstered its oncology portfolio via the acquisition of Exact Sciences.
2. Guardant Health, Inc. (GH): A direct competitor developing its own multi-cancer screening tools alongside its colorectal cancer blood test.
3. Illumina, Inc. (ILMN): The former parent company and current sequencing hardware provider for the Galleri platform.
4. Natera, Inc. (NTRA): A major peer in precision oncology focusing on minimal residual disease (MRD) and recurrence monitoring.

Strategic Outlook and Innovation

GRAIL’s 2026 strategy focuses on "The Path to Reimbursement," including active support for the MCED Readiness Act to enable Medicare coverage. Analysts project steady revenue growth as Galleri is adopted as a supplemental screening tool. The company remains well-capitalized to fund its intensive R&D and clinical trial pipelines.

Innovation at GRAIL is currently focused on a "second-generation" platform to enhance sensitivity for early-stage (Stage I and II) cancers. By integrating methylation technology with additional "omic" markers, GRAIL seeks to maintain its lead in the projected $70 billion early detection market. As an independent company, GRAIL is positioned to execute a flexible, pure-play strategy at the forefront of the next generation of diagnostics.

Want more examples? GRAB Covered Calls | GRBK Covered Calls